Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
100% agree with you Dave.
If they get saliva right, it will put them in a fantastic place.
Technic, on your last comment, Defo some fishy ones on here:) lol
Which bodes well for BC buy out in the same fashion if gdr can get saliva/ bead to perform to a good standard.
The whole diagnostics industry is a little skewed. Abbott have invested tens of millions and bought several companies in order to scale up their Binax test and get it out. Even Abbot's latest claims are based on trial data of 102 samples, woeful and not sure how you can make your claims like that, their first product had similar claims and they had to back track. The whole industry is being bizarrely free with their claims regardless of size or reputation. GDR will have a place, it will sell product and it will support its non-covid products, some of which are making £m's in revenue already (US-DOD biothreat). I continue to be a LTH here. Great product, responsible BOD, some carp PIs.
https://cen.acs.org/analytical-chemistry/diagnostics/COVID-19-antigen-assay-set/98/i34
Technik,
Bigal quoted you initially in an attempt to add weight to his bull****- not me. Go back and check.
LP, you are misquoting me, I did not make those references to Abbots BinaxNOWTM COVID-19 Ag Card test, I made an assertion that a new entrant into the diagnostics market doesn't know the production issues that are ahead of them, making a robust product is key and creating that rigor within a business is difficult. I am unsure why you are quoting me along the lines you are.
Bigal,
You're another liar.
Your initial point was on no evidence of these being used in any market.. don't change the goalposts after i provide evidence.
And i quote 'but the article is littered with terms like 'could be', 'could potentially', 'scientists estimate'. If its still in the hands of the scientists it's not near market yet.'
*Bull****er - the test has been approved for sales in India - so it is very close to the market.
And then,
'The problem with non-commercial groups is they don't know what they don't know, so the enthusiasm is there but the realities of delivering a robust, sensitive test have not yet set in. Manufacture introduces all manner of variables.'
There is no scientific estimate, your and techniks thoughts on it being a 'nearly' test is factually incorrect, as the indian have approved it.. something GDRs test is yet to achieve. You further attempt to devalue the potential of the test by noting the variables in the manufacturing.. well, they have overcome them also haven't they.
You lot just don't like facts but much prefer living in your bull**** bubble.
PS: Here is trump purchasing 150M paper tests - https://www.nytimes.com/2020/09/28/health/trump-coronavirus-testing-rapid.html
Oh and here is the FDA approval for said test also - https://www.fda.gov/media/141570/download
Here is a picture for you - https://www.google.com/search?q=BinaxNOWTM+COVID-19+Ag+Card&rlz=1C1CHBF_en-GBGB910GB910&sxsrf=ALeKk02E7XD-W6vQ8MjcV49g7qEbDNMCWQ:1603696995462&source=lnms&tbm=isch&sa=X&ved=2ahUKEwjopfft3NHsAhWToFwKHbocAwYQ_AUoAnoECBgQBA&biw=1422&bih=642
There are $5 each - much cheaper than ours.
Anyone else want to bull**** let me know :) I am happy to provide evidence to one and all.
@LP,
So All 'could do' and 'supposedly' then ?
You have no evidence of any Sells, just as I thought.
kit was created at the Council of Scientific and Industrial Research's constituent lab, part of the Institute of Genomics and Integrative Biology (CSIR-IGIB) in New Delhi.
And has been approved.
You don’t need specific sales figures to understand that an Indian developed test, approved & considered a testing breakthrough will be commercialised well in its own country. Seriously, you’re not that dopey surely.
@LP,
I ignored your post as just another of your 'ANTI GDR POSTS', and NOT Worthy - India's drug authority approved paper-strip Covid-19 test that 'could return' results within hour. (key words 'could return'). Also - No evidence it is being used.
As I posted - All 'Could Be' and 'Supposedly', as per your evidence - this is not evidence that paper tests are being used in India or anywhere else - Please do better LP - You seem to have lost your way, in more ways than just this one !
BigJock,
What a name for starters.
Bigal requested evidence to support the commercialisation of these new paper tests, all i did was provide it.
I am really sorry facts and reason are a tad difficult for you to digest. Hopefully MOIL will post another lie tomorrow morning to steady your ship.
And what...
Have you seen the size of India. I am really confused, are you invested here because all you want to do is shoot this stock to pieces
https://edition.cnn.com/2020/10/05/india/india-covid-19-hour-tests-approved-intl/index.html
There's your evidence.
@Honkeydonkey,
Paper Tests are all 'could be' and 'supposedly' ??
Do you have any evidence/links that these Paper Tests are being used in India or any where else, as a 'Standard Test' for COVID-19 ?
Technick posted a very enlightening comment on Paper Tests, earlier this month:-
This is what Technick posted about CRISP:
Been in this game a long time and seen a lot of these tests trying to be developed. CRISPR has been around a while as a game changer in the making for gene editing, it hasn't come out of research. Then over the last couple of years it was suggested it might now be a useful diagnostic tool. But it didn't. I'm not saying it won't, but the article is littered with terms like 'could be', 'could potentially', 'scientists estimate'. If its still in the hands of the scientists it's not near market yet.
The problem with non-commercial groups is they don't know what they don't know, so the enthusiasm is there but the realities of delivering a robust, sensitive test have not yet set in. Manufacture introduces all manner of variables.
Not saying it won't get there, we need cheaper tools and in particular for ultra high screening volumes.
All these technologies have their places. GDR is positioning itself. The benefit is the same test is lab and POC deployable.
My biggest worry going forward are the paper tests which supposedly have a high rate of sensitivity.....they have started using them in India and Sherlock bio have eua in the states....